• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, August 16, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Utilization and cancer yield of BI-RADS 3 lesions detected on high risk screening breast MRI

Bioengineer by Bioengineer
May 7, 2019
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Results to be exhibited at 2019 ARRS Annual Meeting

Leesburg, VA, May 7, 2019–When appropriate, short-interval follow-up magnetic resonance imaging (MRI) can be used to identify early stage breast cancer and avoid unnecessary biopsies, according to a study to be presented at the ARRS 2019 Annual Meeting, set for May 5-10 in Honolulu, HI.

Utilization of MRI for breast cancer screening continues to increase, as it is the most sensitive modality to detect breast cancer. Yet, much more is known about short-term follow-up of probably benign findings (

Among the 6672 MRI screening exams performed in 3214 patients included in the study, 202 (3.0%) were assigned a BI-RADS 3. Among baseline exams, 8.3% (82/983) were assigned BI-RADS 3, compared to 2.1% (120/5689) of non-baseline exams (p

The results indicate BI-RADS 3 assessments are significantly more common in baseline versus non-baseline screening breast MRI exams, and BI-RADS 3 lesions on baseline exams have a lower cancer yield. Most cancers diagnosed on follow-up of BI-RADS 3 lesions are early stage and most are diagnosed at or before the 6-month follow-up. The results indicate that when employed sensibly, short-interval follow-up MRI is an appropriate technique to identify early stage breast cancer. “This study clarifies that probably benign assessments can be as useful for MRI as they are for mammography,” said co-author Leslie Lamb, MD, MSc, of Massachusetts General Hospital (MGH) and Harvard Medical School, both in Boston.

“Many patients and providers question the utility of BI-RADS 3 in MRI, particularly as some insurers do not cover the costs of the short interval follow-up MRIs. This study clarifies that short interval follow-up MRI is a valuable method of identifying early stage breast cancer while avoiding unnecessary biopsies.” noted co-author Christine Edmonds, MD, of the department of radiology at MGH.

###

With educational activities representing the entire spectrum of radiology, ARRS will host leading radiologists from around the world at the ARRS 2019 Annual Meeting, May 5-10, at the Hawaii Convention Center in Honolulu, Hawaii. For more information, visit: http://www.arrs.org/am19.

Media Contact
Alycia Tessean
[email protected]
https://arrs.org/ARRSLIVE/Pressroom/PressReleases/bi-rads-breast-mri-utilization-and-cancer-yield.aspx

Tags: Breast CancercancerDiagnosticsHealth Care Systems/ServicesHealth ProfessionalsMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Lipid droplet signatures classify liver cancer and reveal PLIN3 therapeutic potential

August 15, 2026

4D-Printed Breast Cancer Model Mimics Ducts, Revealing Treatment Resistance

August 15, 2026

Monocyte-derived IL-1β/p65/KRT7/ILK pathway drives epithelial–mesenchymal transition in colorectal cancer

August 15, 2026

DKMS Opens John Hansen Grant: Nearly €1 Million for Blood Cancer Research

August 15, 2026
Please login to join discussion

POPULAR NEWS

  • KAIST develops semiconductor neuron that harnesses noise to selectively process signals

    29 shares
    Share 12 Tweet 7
  • Imagining natural and extra robotic thumbs together strengthens kinesthetic sensorimotor networks

    29 shares
    Share 12 Tweet 7
  • PARP1 Drives Neuropathic Pain Through GPX4-Dependent Ferroptosis in Injured Mice’s Sensory Neurons

    29 shares
    Share 12 Tweet 7
  • Strubbelig–NHL3 Receptor Complex Helps Arabidopsis Respond to Cellulose Deficiency

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

KAIST develops semiconductor neuron that harnesses noise to selectively process signals

Imagining natural and extra robotic thumbs together strengthens kinesthetic sensorimotor networks

PARP1 Drives Neuropathic Pain Through GPX4-Dependent Ferroptosis in Injured Mice’s Sensory Neurons

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.